Biotech Values

[DewDiligence]

Clinical / Regulatory / Litigation Calendar

[Please keep these entries up to date! See
the updating procedure at the end of this post.
Items that are out of date will be removed.]

NOTE: ANYONE MAY UPDATE THIS FILE


Edits: BMY (Yervoy ph3 in CRPC completed—entry removed); ENTA; MNTA.


ABBV – HCV program: see ENTA.

ABT – ‘Absorb’ bioresorbable stent: US launch possible in 2013, pending clinical results. (Launched in 30 countries including EU 9/25/12.)

AMGN – Xgeva sBLA submission for bone health in non-metastatic cancer: 2013 pending results of phase-3 trial in breast cancer.

BMY – Eliquis: see PFE.

ENTA/ABBV – All six ph3 trials of ABT-450 + ABT-267 + ABT-333 that will be part of initial NDA/MAA were fully enrolled as of 7/26/13; NDA/MAA submissions 2Q14, which is same quarter as GILD’s all-oral submissions in GT1 patients.
.
ENTA/NVS – EDP-239 ph1b monotherapy trial started by NVS Jun 2013, exp to complete Jun 2014; DDI study (presumably with DEB025) started by NVS Jul 2013, but no details (yet) on ctg.

GILD – Sofosbuvir + riba + pegIFN (for GT1) NDA: FDA advisory panel 10/25/13, PDUFA date 12/8/13.
GILD – ION-2 and ION-3 ph3 data (Sofobusvir + GS-5885 ± riba): 4Q13; ION-1 ph3 data (same regimen): 1Q14.
GILD – NDA submission for Sofosbuvir + GS-5885 ± riba: 2Q14.

GILD –‘Quad Prime’ based on TAF (f/k/a GS-7340): Data from two phase-2 studies early 2013—one tests Quad Prime vs Atripla and one tests Quad Prime vs Prezista + Cobicstat + Truvada. (Ph2 testing Quad Prime vs Stribild reported 10/31/12.)
GILD – “Standalone” Evitegravir NDA: FDA issued CRL on 4/29/13; no further details available. (Note: Evitegravir is one of the component drugs in Stribild.)
GILD – “Standalone” Cobicstat NDA: FDA issued CRL on 4/29/13; no further details available. MAA submitted 5/23/12; no further info available. (Note: Cobicstat is one of the component drugs in Stribild.)

IDIX – IDX719 (NS5A inhibitor, now IDIX’s lead drug): 3-day PoC phase-1b monotherapy data reported 6/20/12.

ITMN – Pirfenidone: No specific timeline for response to FDA’s CRL of 5/4/10 requesting a new trial.

JNJ – Xarelto second sNDA in PCI sub-indication of ACS issued 6/28/13; a new-trial requirement seems likely in this indication.

LGND - Promacta for HCV: EU MAA submitted 5/30/12. (Approved by FDA 11/19/12.)

MNTA – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90636955 .

NVS – HCV program: see ENTA.

PFE – Eliquis sNDA in primary VTE prevention: PDUFA date 3/15/14; Eliquis sNDA in VTE treatment & secondary prevention: FDA submission 3Q13. (Eliquis was approved for VTE prevention in EU in 2011.)

PRAN - Reach2HD Phase-2 for Huntington's disease: Results October, 2013
PRAN - IMAGINE: Phase-2 imaging trial for Alzheimer's disease. Plaque positive prodromal and mild AD. Last Patient to be Dosed November 2013; Trial will be completed in December, 2013.

SNY – Lemtrada for RRMS: PDUFA date late 2013; (CHMP approval 6/26/13).

TEVA – Thrice-weekly formulation of Copaxone: PDUDA date Jan 2014 (assuming standard review).

--
Procedure for Updating Calendar

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old calendar.

2. Make your additions or modifications, inserting new items in alphabetical order.

3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).